Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | ANPEP | P15144 | 2/20 | 0.47 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.47 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ACP3 | P15309 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11836621 | 0.89 | MMP12 (0.58) | TSHRMMEHTT | |
| SCHEMBL3974022 | 0.86 | MAPT (0.52) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL3409877 | 0.85 | MAPT (0.55) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL5046410 | 0.85 | MAPT (0.55) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL16315019 | 0.82 | CYP1A2 (0.45) | CYP1A2SMN1; SMN2ALDH1A1 | |
| SCHEMBL17590597 | 0.82 | TAAR1 (0.45) | SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL2291948 | 0.80 | MMP8 (0.56) | CNR2TSHRKEAP1ANPEPERAP1 | |
| SCHEMBL17022224 | 0.78 | CYP1A2 (0.61) | CYP1A2PPARGPPARA | |
| SCHEMBL22863218 | 0.78 | CYP1A2 (0.61) | CYP1A2PPARGPPARA | |
| SCHEMBL1567341 | 0.78 | CYP1A2 (0.61) | CYP1A2PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2033635-A1 | Short-chain fatty acid derivatives for treating pruritus | Asan Laboratories Company (Cayman) Limited (CN) | 2009-03-11 | — | — | EP | claimed |
| US-20080107646-A1 | Administering phenylbutyric acid derivative and pharmaceutically acceptable carrier | Sunny Pharmtech Inc. (TW) | 2008-05-08 | — | — | US | claimed |
| US-6403646-B1 | ADMINISTERING PHENYLBUTYRIC ACID OR DERIVATIVES TO TREAT LIVER DISEASE AND EMPHYSEMA CAUSED BY PROTEASE INHIBITOR TYPE Z MUTATION; STIMULATES SECRETION WITHOUT INCREASING SYNTHESIS OF PROTEIN | PERLMUTTER DAVID H (US) | 2002-06-11 | — | — | US | claimed |
| WO-2025035608-A1 | GLUTAMIC ACID UREA COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF, NUCLIDE TARGETING PROBE AND PREPARATION METHOD THEREFOR AND USE THEREOF, AND PHARMACEUTICAL COMPOSITION | 厦门大学 | 2025-02-20 | — | — | WO | disclosed |
| US-20240050600-A1 | Radiopharmaceuticals, uses thereof, and methods for the production thereof | Clarity Pharmaceuticals Ltd (AU) | 2024-02-15 | — | — | US | disclosed |
| EP-4196175-A1 | RADIOPHARMACEUTICALS, USES THEREOF, AND METHODS FOR THE PRODUCTION THEREOF | Clarity Pharmaceuticals Ltd (AU) | 2023-06-21 | — | — | EP | disclosed |
| CN-110740757-B | Novel PSMA-binding agents and uses thereof | 同位素技术慕尼黑公司 | 2023-04-04 | — | — | CN | disclosed |
| WO-2022032353-A1 | RADIOPHARMACEUTICALS, USES THEREOF, AND METHODS FOR THE PRODUCTION THEREOF | Clarity Pharmaceuticals Ltd (AU) | 2022-02-17 | — | — | WO | disclosed |
| CN-110740757-A | Novel PSMA-binding agents and uses thereof | 同位素技术慕尼黑公司 | 2020-01-31 | — | — | CN | disclosed |
| WO-2018233798-A1 | NOVEL PSMA-BINDING AGENTS AND USES THEREOF | ITM Isotopen Technologien München AG (DE) | 2018-12-27 | — | — | WO | disclosed |
| US-8846039-B2 | Method for ameliorating pruritus | ASAN LABORATORIES COMPANY (CAYMAN), LIMITED (TW) | 2014-09-30 | — | — | US | disclosed |
| US-5710178-A | ARYL- AND ARYLOXYALKANOIC ACIDS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-01-20 | — | — | US | disclosed |
| US-5708025-A | BY INDUCING PRODUCTION OF FETAL HEMOGLOBINS BY ADMINISTERING SPECIFIED ARYL ACIDS, DERIVATIVES, SALTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-01-13 | — | — | US | disclosed |
| US-5661179-A | ADMINISTERING; TREATS NEUROBLASTOMA, MYELODYSPLASIA, NON-SMALL CELL LUNG CANCER, PROSTATE CANCER, MELANOMA, BRAIN TUMOR, KAPOSI'S SARCOMA, LYMPHOMA, LEUKEMIA, BREAST AND LUNG CANCER, OSTEOSARCOMA AND FIBROSARCOMA | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-08-26 | — | — | US | disclosed |
| US-5654333-A | THERAPY FOR ANEMIA, CANCER, AIDS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-08-05 | — | — | US | disclosed |
| US-5635533-A | ANTITUMOR AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-06-03 | — | — | US | disclosed |
| US-5635532-A | ADMINISTERING PHENYL OR NAPHTHYL ACETIC ACID DERIVATIVES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-06-03 | — | — | US | disclosed |
| US-5605930-A | ADMINISTERING PHENYLACETIC ACID AS AN INHIBITOR OF THE MEVALONATE PATHWAY | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-02-25 | — | — | US | disclosed |
| EP-0725635-A1 | PHENYLACETATE AND DERIVATIVES ALONE OR IN COMBINATION WITH OTHER COMPOUNDS AGAINST NEOPLASTIC CONDITIONS AND OTHER DISORDERS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-08-14 | — | — | EP | disclosed |
| WO-1995010271-A2 | PHENYLACETATE AND DERIVATIVES ALONE OR IN COMBINATION WITH OTHER COMPOUNDS AGAINST NEOPLASTIC CONDITIONS AND OTHER DISORDERS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050600-A1 | Radiopharmaceuticals, uses thereof, and methods for the production thereof | GRPR, OGFR, GHRHR | CNR2 843/4885TSHR 147/4885KEAP1 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.